Alnylam Pharmaceuticals
ALNY
#630
Rank
โ‚น2.741 T
Marketcap
โ‚น21,255
Share price
-1.16%
Change (1 day)
39.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น354.72. In 2022 the company made an earnings per share (EPS) of -โ‚น801.79 a decrease over its 2021 EPS that were of -โ‚น621.41.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-57.94%
2022-โ‚น801.7929.03%
2021-โ‚น621.41-3.36%
2020-โ‚น642.99-8.48%
2019-โ‚น702.547.67%
2018-โ‚น652.4839.74%
2017-โ‚น466.9212.94%
2016-โ‚น413.4138.84%
2015-โ‚น297.76-32.88%
2014-โ‚น443.62259.44%
2013-โ‚น123.42-31.25%
2012-โ‚น179.5252.94%
2011-โ‚น117.3830.77%
2010-โ‚น89.76-8.77%
2009-โ‚น98.3978.13%
2008-โ‚น55.24-70.78%
2007-โ‚น189.0199.09%
2006-โ‚น94.94-43.88%
2005-โ‚น169.16-82.33%
2004-โ‚น957.44-59.23%
2003-โ‚น2,348

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น146.72-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,224-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น675.78 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.30-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น145.86-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น322.79-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น274.48-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น172.61-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel